EyePoint Shares Crash After Duravyu Phase 3 Stumble in Wet AMD, But Treatment Burden Reduction Shines on August 18, 2026 aflibercept BCVA Duravyu EyePoint Eylea EYPT LUCIA trial LUGANO Phase 3 stock plunge treatment burden reduction wet AMD +
FDA Grants Regeneron Two Eylea HD Approvals in One Day on November 21, 2025 aflibercept Approved dosing Eylea Hodgkin Disease Macular retinal edema monthly Ophthalmology specialty Regeneron Retinal Vein Occlusion RVO United States Food and Drug Administration +